Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • Nuheara secures NDIS eligibility funding for smart hearing solutions
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Nuheara secures NDIS eligibility funding for smart hearing solutions
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • Nuheara secures NDIS eligibility funding for smart hearing solutions
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • Nuheara secures NDIS eligibility funding for smart hearing solutions
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • Nuheara secures NDIS eligibility funding for smart hearing solutions
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Nuheara collapses after failing to renegotiate debt obligations
    Nuheara collapses after failing to renegotiate debt obligations
    • News

  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

  • Careteq further penetrates its large and growing addressable market
    Careteq further penetrates its large and growing addressable market
    • News

  • Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
    • News

  • It’s not coming home but English soccer fans could soon have beers delivered to their seats
    It’s not coming home but English soccer fans could soon have beers delivered to their seats
    • News

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.